From: Multicentre clinical radiotherapy audit in rectal cancer: results of the IROCA project
INDICATORS | ICO-B | ICO-G | ICO H | IPO | NO | WCO | All | ||
---|---|---|---|---|---|---|---|---|---|
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N | % | P | |
Diagnosed at a different hospital | 23 (57.5) | 33 (82.5) | 37 (92.5) | 38 (97.4) | 12 (54.5) | 37 (92.5) | 180 | 81.4 | 0.000 |
Pre-treatment MRI | 34 (85.0) | 40 (100) | 40 (100) | 24 (61.5) | 18 (81.8) | 37 (92.5) | 193 | 87.3 | 0.000 |
Pre-treatment pelvic US | 16 (40.0) | 3 (7.5) | 17 (42.5) | 17 (43.6) | 5 (22.7) | 3 (7.5) | 61 | 27.6 | 0.000 |
Pre-treatment thoracoabdominal CT | 40 (100) | 40 (100) | 39 (97.5) | 37 (94.9) | 19 (86.4) | 6 (15.0) | 181 | 81.9 | 0.000 |
TNM staging | 40 (100) | 39 (97.5) | 40 (100) | 35 (89.7) | 22 (100) | 39 (97.5) | 215 | 97.3 | 0.046 |
MRI staging | 36 (90) | 34 (85.0) | 36 (90) | 4 (10.3) | 0 (0.0) | 38 (95.0) | 148 | 67.0 | 0.000 |
Presented to MTB | 25 (62.5) | 20 (50.0) | 34 (85.0) | 39 (100) | 11 (50.0) | 38 (95.0) | 167 | 75.6 | 0.000 |
Presented at pre-treatment RO clinical session | 40 (100) | 40 (100) | 39 (97.5) | 0 (0.0) | 22 (100) | 0 (0.0) | 141 | 63.8 | 0.000 |
Time between biopsy and first visit at RO (±4) [days] | 32.6 | 30.5 | 39.2 | 58.6 | 45.9 | 21.6 | 210 | 37.6 | < 0.001 |
Time between first visit at RO and beginning of RT [days] | 15.1 | 16.5 | 19.7 | 16.0 | 28.5 | 38.8 | 221 | 22.0 | < 0.001 |